Skip to main content
Premium Trial:

Request an Annual Quote

Sensium Technologies Expands License to Protein Biochip Technology

NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.

Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.

Known as heterodimer protein technology, the intellectual property in the license covers the capture and detection of proteins binding to a surface. Sensium is using the technology, along with separate molecular sensing technology, in protein biochips and other tools to discover and develop diagnostics and pharmaceuticals.

Helix BioPharma is the majority owner of Sensium, with outside investors holding 24 percent of its stock. Sensium’s board of directors includes Paul Russo, CEO of Genesis Microchip, and Robert Hodges, a Univerisity of Alberta Researcher and CEO of PENCE.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.